NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

中國的Moxifloxacin市場分析 (2021年∼2025年)

Investigation Report on China's Moxifloxacin Market 2021-2025

出版商 China Research and Intelligence 商品編碼 1010190
出版日期 內容資訊 英文 50 Pages
商品交期: 最快1-2個工作天內
價格
中國的Moxifloxacin市場分析 (2021年∼2025年) Investigation Report on China's Moxifloxacin Market 2021-2025
出版日期: 2021年06月08日內容資訊: 英文 50 Pages
簡介

Moxifloxacin,是Bayer Vital GmbH開發的第4代的合成奎諾酮類抗生素(8-methoxy-fluoroquinolone 抗生素)。中國也在2002年發售。

中國國內的Moxifloxacin的銷售額,從2016年到2019年擴大,不過,2020年急速減少。銷售額2019年為18億8200萬人民幣,2020年為11億600萬人民幣 (減少41.23%) 。一般認為2021年新型冠狀病毒感染疾病 (COVID-19) 感染擴大趨於平靜,2025年將繼續擴大趨勢。

中國的Moxifloxacin市場,2020年時刻有19家公司進入。今後將有更多新廠商加入,預計價格下降和銷售量、銷售額擴大。

本報告提供中國的Moxifloxacin的市場相關分析,產品的概要和授權情形,整體市場規模趨勢預測,各地區的詳細趨勢,市場價格趨勢預測,主要企業的簡介與市場佔有率,主要的推動及阻礙市場要素,新型冠狀病毒感染疾病 (COVID-19)的影響等資訊彙整,為您概述為以下內容。

目錄

第1章 Moxifloxacin的相關概念

  • Moxifloxacin的適應症
  • 中國國內的Moxifloxacin的開發趨勢
  • 中國政府的Moxifloxacin的核準情況
  • COVID-19對中國的Moxifloxacin銷售的影響

第2章 中國國內的Moxifloxacin銷售趨勢 (2016年∼2020年)

  • Moxifloxacin的銷售額
    • 整體銷售額
    • 各地區的銷售額
  • Moxifloxacin的銷售量
    • 整體銷售量
    • 各地區的銷售量
  • 中國國內的Moxifloxacin銷售趨勢:各劑型 (2016年∼2020年)
    • 投入的藥劑
    • 錠劑
    • 點眼藥劑

第3章 中國的Moxifloxacin主要製造商分析 (2016年∼2020年)

  • 主要Moxifloxacinmeka的市場佔有率分析
    • 市場佔有率:銷售額為基礎
    • 市場佔有率:銷售量為基礎
  • Bayer Vital GmbH
    • 企業簡介
    • 中國的Moxifloxacin銷售趨勢
  • Nanjing Yoko Pharmaceutical Group Co., Ltd.
  • Chengdu Tiantaishan Pharmaceutical Co., Ltd.
  • Chengdu Zhengkang Pharmaceutical Co., LTD.
  • Jiangsu Zhengda Fenghai Pharmaceutical Co. Ltd.

第4章 中國的Moxifloxacin的價格趨勢:各主要製造商 (2020年∼2021年)

  • Bayer Vital GmbH (AVELOX)
  • Nanjing Yoko Pharmaceutical Group Co., Ltd. (PRIMENOR)
  • Chengdu Tiantaishan Pharmaceutical Co., Ltd.
  • Chengdu Zhengkang Pharmaceutical Co., LTD.
  • Jiangsu Zhengda Fenghai Pharmaceutical Co. Ltd. (Fengreineng)

第5章 中國的Moxifloxacin市場未來展望 (2021年∼2025年)

  • 左右中國的Moxifloxacin市場趨勢的要素
    • COVID-19對中國的Moxifloxacin市場的影響
    • 市場促進因素和機會
    • 市場威脅與課題
  • 市場規模的預測
  • 市場趨勢的預測
目錄
Product Code: 2106518

Moxifloxacin is a fourth-generation synthetic quinolone antibacterial drug (8-methoxy-fluoroquinolone antibiotic) developed by Bayer Vital GmbH. It was approved for marketing by the FDA in December 1999. Moxifloxacin can be used to treat several infections, including respiratory infections, cellulitis, anthracnose, endocarditis, intra-abdominal infections, meningitis and tuberculosis. In 2002, Moxifloxacin tablets (400mg) were launched in China. In 2004, Moxifloxacin injection was launched for the treatment of adults suffering from upper and lower respiratory tract infections. In the first half of 2021, in addition to Bayer Vital GmbH, there are several manufacturer in the Moxifloxacin market in China, such as Nanjing Youke Pharmaceutical Co., Ltd., Chengdu Tiantaishan Pharmaceutical Co., Ltd., Chengdu Zhengkang Pharmaceutical Co., Ltd. and Jiangsu Zhengda Fenghai Pharmaceutical Co., Ltd.

CRI's survey data shows that the sales value of Moxifloxacin has grown steadily from 2016 to 2019 in China. In 2020, the sales value of Moxifloxacin fell by 41.23% in China, from CNY1.882 billion in 2019 to CNY1.106 billion in 2020. Due to the second batch of state-organized centralized procurement of medicines, and manufacturers of Moxifloxacin compete by reducing prices. Moxifloxacin of Bayer Vital GmbH dropped by 77.70%, and Moxifloxacin of Nanjing Youke Pharmaceutical Co., Ltd. dropped by 53.07%. The CAGR of the sales value of Moxifloxacin in 2016-2020 is -3.76% in China.

CRI predicts that with the effective relief of the COVID-19 epidemic, the sales of Moxifloxacin in the Chinese market will have a recovery growth in 2021-2025. In addition, there are 19 pharmaceutical companies that have entered the Chinese Moxifloxacin market by 2020. It is expected that the price of Moxifloxacin will decline with the addition of new manufacturers, and there is room for growth in sales volume and sales. At the same time, compared with similar drugs, Moxifloxacin has a broad antibacterial spectrum, strong curative effect and other advantages, so the sales volume of Moxifloxacin in China will maintain a growth trend.

Topics Covered:

  • The impact of COVID-19 on China's Moxifloxacin market
  • Sales value of China's Moxifloxacin 2016-2020
  • Competitive landscape of China's Moxifloxacin market
  • Prices of Moxifloxacin in China
  • Prices of Moxifloxacin in China by regions and manufacturers
  • Analysis on factors affecting the development of China's Moxifloxacin market
  • Prospect of China's Moxifloxacin market from 2021 to 2025

Table of Contents

1 Relevant Concepts of Moxifloxacin 1.1 Indications for Moxifloxacin

  • 1.2 Development of Moxifloxacin in China
  • 1.3 Governmental Approval of Moxifloxacin in China
  • 1.4 The Impact of COVID-19 on Moxifloxacin sales in China

2 Sales of Moxifloxacin in China, 2016-2020

  • 2.1 Sales Value of Moxifloxacin
    • 2.1.1 Overall Sales Value
    • 2.1.2 Sales Value by Region
  • 2.2 Sales Volume of Moxifloxacin
    • 2.2.1 Overall Sales Volume
    • 2.2.2 Sales Volume by Region
  • 2.3 Sales of Moxifloxacin by Dosage Form in China, 2016-2020
    • 2.3.1 Injection
    • 2.3.3 Tablets
    • 2.3.3 Eye Drop

3 Analysis of Major Moxifloxacin Manufacturers in China, 2016-2020

  • 3.1 Analysis of Market Share of Major Moxifloxacin Manufacturers
    • 3.1.1 Investigation on Market Share by Sales Value
    • 3.1.2 Investigation on Market Share by Sales volume
  • 3.2 Bayer Vital GmbH
    • 3.2.1 Enterprise Profile
    • 3.2.2 Sales of AVELOX (Bayer Vital GmbH's Moxifloxacin) in China
  • 3.3 Nanjing Yoko Pharmaceutical Group Co., Ltd.
    • 3.3.1 Enterprise Profile
    • 3.3.2 Sales of PRIMENOR (Nanjing Yoko Pharmaceutical Group Co., Ltd.'s Moxifloxacin) in China
  • 3.4 Chengdu Tiantaishan Pharmaceutical Co., Ltd.
    • 3.4.1 Enterprise Profile
    • 3.4.2 Sales of Chengdu Tiantaishan Pharmaceutical Co., Ltd.'s Moxifloxacin in China
  • 3.5 Chengdu Zhengkang Pharmaceutical Co., LTD.
    • 3.5.1 Enterprise Profile
    • 3.5.2 Sales of Chengdu Zhengkang Pharmaceutical Co., LTD.'s Moxifloxacin in China
  • 3.6 Jiangsu Zhengda Fenghai Pharmaceutical Co. Ltd.
    • 3.6.1 Enterprise Profile
    • 3.6.2 Sales of Fengreineng (Jiangsu Zhengda Fenghai Pharmaceutical Co. Ltd.'s Moxifloxacin) in China

4 Prices of Moxifloxacin for Different Manufacturers in China, 2020-2021

  • 4.1 Bayer Vital GmbH (AVELOX)
  • 4.2 Nanjing Yoko Pharmaceutical Group Co., Ltd. (PRIMENOR)
  • 4.3 Chengdu Tiantaishan Pharmaceutical Co., Ltd.
  • 4.4 Chengdu Zhengkang Pharmaceutical Co., LTD.
  • 4.5 Jiangsu Zhengda Fenghai Pharmaceutical Co. Ltd. (Fengreineng)

5 Prospect of Chinese Moxifloxacin Market, 2021-2025

  • 5.1 Influential Factors of Chinese Moxifloxacin Market Development
    • 5.1.1 The Impact of COVID-19 on Chinese Moxifloxacin Market
    • 5.1.2 Market Drivers and Opportunities
    • 5.1.3 Market Threats and Challenges
  • 5.2 Forecast on Market Size
  • 5.3 Forecast on Market Trend

List of Charts

  • Chart Patent Information About Moxifloxacin Injection Registration in China
  • Chart Patent Information About Moxifloxacin Tablets Registration in China
  • Chart Patent Information About Moxifloxacin Eye Drop Registration in China
  • Chart Sales Value of Moxifloxacin Injection over the World
  • Chart Sales Value of Moxifloxacin Tablets over the World
  • Chart Sales Value of Moxifloxacin Eye Drop over the World
  • Chart Sales Value of Moxifloxacin Injection in China, 2016-2020
  • Chart Sales Value of Moxifloxacin Tablets in China, 2016-2020
  • Chart Sales Value of Moxifloxacin Eye Drop in China, 2016-2020
  • Chart Sales Value of Moxifloxacin Injection in China by Region, 2016-2020
  • Chart Sales Value of Moxifloxacin Tablets in China by Region, 2016-2020
  • Chart Sales Value of Moxifloxacin Eye Drop in China by Region, 2016-2020
  • Chart Sales Volume of Moxifloxacin Injection in China, 2016-2020
  • Chart Sales Volume of Moxifloxacin Tablets in China, 2016-2020
  • Chart Sales Volume of Moxifloxacin Eye Drop in China, 2016-2020
  • Chart Sales Volume of Moxifloxacin Injection in China by Region, 2016-2020
  • Chart Sales Volume of Moxifloxacin Tablets in China by Region, 2016-2020
  • Chart Sales Volume of Moxifloxacin Eye Drop in China by Region, 2016-2020
  • Chart Market Share by Sales Value of Top Moxifloxacin Injection Manufacturers in China, 2016-2020
  • Chart Market Share by Sales Value of Top Moxifloxacin Tablets Manufacturers in China, 2016-2020
  • Chart Market Share by Sales Value of Top Moxifloxacin Eye Drop Manufacturers in China, 2016-2020
  • Chart Sales Value and Volume of AVELOX in China, 2016-2020
  • Chart Sales Value and Volume of PRIMENOR in China, 2016-2020
  • Chart Sales Value and Volume of Chengdu Tiantaishan Pharmaceutical Co., Ltd.'s Moxifloxacin in China, 2016-2020
  • Chart Sales Value and Volume of Chengdu Zhengkang Pharmaceutical Co., LTD.'s Moxifloxacin in China, 2016-2020
  • Chart Sales Value and Volume of Fengreineng in China, 2016-2020
  • Chart Referential Prices of AVELOX in China by Region, 2020-2021
  • Chart Referential Prices of PRIMENOR in China by Region, 2020-2021
  • Chart Referential Prices of Chengdu Tiantaishan Pharmaceutical Co., Ltd.'s Moxifloxacin in China by Region, 2020-2021
  • Chart Referential Prices of Chengdu Zhengkang Pharmaceutical Co., LTD.'s Moxifloxacin in China by Region, 2020-2021
  • Chart Referential Prices of Fengreineng in China by Region, 2020-2021
  • Chart Forecast on Sales Value of Moxifloxacin Injection in China, 2021-2025
  • Chart Forecast on Sales Value of Moxifloxacin Tablets in China, 2021-2025
  • Chart Forecast on Sales Value of Moxifloxacin Eye Drop in China, 2021-2025
  • Chart Forecast on Sales Volume of Moxifloxacin Injection in China, 2021-2025
  • Chart Forecast on Sales Volume of Moxifloxacin Tablets in China, 2021-2025
  • Chart Forecast on Sales Volume of Moxifloxacin Eye Drop in China, 2021-2025